pISSN 1976-2283
eISSN 2005-1212

Cited by CrossRef (5)

  1. Leif Angelison, Sven Almer, Loa Davidsdottir, Per Hammarlund, Stefan Lindgren, Ulf Hindorf, Jan Marsal, Erik Hertervig. Short and long-term efficacy of adalimumab in ulcerative colitis: a real-life study. Scandinavian Journal of Gastroenterology 2020:1
    https://doi.org/10.1080/00365521.2020.1713210
  2. Einav Srulovici, Vishvas Garg, Adi Ghilai, Becca Feldman, Moshe Hoshen, Ran D. Balicer, Martha Skup, Maya Leventer-Roberts. Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study. Adv Ther 2018;35:655
    https://doi.org/10.1007/s12325-018-0706-0
  3. Jae Hyun Kim, Jae Hee Cheon. Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis. Gut Liver 2016;10:162
    https://doi.org/10.5009/gnl16024
  4. Dong Yeon Jeong, Seung Kim, Min Ji Son, Chei Yun Son, Jong Yeob Kim, Andreas Kronbichler, Keum Hwa Lee, Jae Il Shin. Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review. Autoimmunity Reviews 2019;18:439
    https://doi.org/10.1016/j.autrev.2019.03.002
  5. Katerina Pantavou, Anneza I Yiallourou, Daniele Piovani, Despo Evripidou, Silvio Danese, Laurent Peyrin-Biroulet, Stefanos Bonovas, Georgios K Nikolopoulos. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. United European Gastroenterology Journal 2019;7:1285
    https://doi.org/10.1177/2050640619883566